top of page

Search Results

Results found for "ModMab Therapeutics"

  • 📰 GPCR Weekly News, January 22 to 28, 2024

    Xavier Leroy on his appointment as CEO of GIO Therapeutics! Congratulations to Domain Therapeutics for being awarded the RHU SPRINT consortium grant. Endocrinology, and Taste The Role of Gut Microbiota and Associated Compounds in Cardiovascular Health and its Therapeutic Living Cells with Cucurbit[7]uril and Hemicyanine as a "Turn-On" Fluorescence Probe Industry News Domain Therapeutics Xavier Leroy appointed as CEO of GIO Therapeutics GPCR Events, Meetings, and Webinars NOW!

  • Adenosine receptor signalling in Alzheimer's disease

    Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic

  • Adenosine receptor signalling in Alzheimer's disease

    Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic

  • 📰 GPCR Weekly News, June 12 to 18, 2023

    GPCRs in Neuroscience Orphan receptor GPR88 as a potential therapeutic target for CNS disorders - an Industry News Coherus to Acquire Surface Oncology Confo Therapeutics and AbCellera partner on GPCR-targeting Patent in Japan Proteros Biostructures GmbH Revolutionizes Metabolic Disorder Treatments Structure Therapeutics (June 28 - 30, 2023) NEW FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics

  • How a Failed Experiment Created a Powerful GPCR Imaging Tool

    not just the pancreas This tool helped clarify: Which neurons respond Which cell populations drive therapeutic metabolic therapy Guide how next-generation incretin drugs are designed Support cell-targeted conjugate therapeutic

  • Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success

    That choice determines whether you risk over- or under-dosing, miss safety windows, or miss therapeutic More nuanced control, fewer off-target liabilities, and novel therapeutic windows. Correctly distinguishing these mechanisms helps refine therapeutic index calculations, prioritize safer

  • Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did

    Advances in biased signaling, allosterism, and endosomal signaling have opened new therapeutic frontiers

  • 📰 GPCR Weekly News, May 8 to 14, 2023

    2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Addex Therapeutics Research Council (ERC) Addex Reports Q1 2023 Financial Results And Provides Corporate Update Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights OMass Therapeutics presented at the BioEquity Conference British Patient Capital Invests £10m in next-generation drug development company OMass Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • From Ox Liver to AI: How the History of Pharmacology Shapes Its Future

    👉 Join Terry’s Corner, your essential launchpad into the world of therapeutic science Unlock "The History

  • 📰 GPCR Weekly News, April 17 to 23, 2023

    GPCRs in Neuroscience G protein coupled receptors as targets for transformative neuropsychiatric therapeutics GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor

  • GPCR Happy Hour – Boston, Sept 2025

    delivers cutting-edge imaging and analysis that accelerates the discovery of new and life-changing therapeutics comprehensive approach enables Axxam to support clients worldwide in identifying and optimizing new therapeutic

  • GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!

    Receptor Bryan Roth  and Brian Krumm  for their excellent study on Molecular glues as potential GPCR therapeutics November 7th : Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th : Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. modulation of the prostaglandin EP4 receptor GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics

  • 📰 GPCR Weekly News, July 1 to 7, 2024

    September 5th to 26th, 2024 Overview: GPCRs have been and arguably still are the most prolific and fertile therapeutic trade-offs in whitefly G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic proteins block the internalization of cognate GPCRs and disrupt downstream intracellular signaling Therapeutic acute and chronic relaxin-3 receptor (RXFP3) activation in the rat retrosplenial cortex Unveiling the therapeutic

  • Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Industry News MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 Certa Therapeutics proteins for biology and health research Innovate UK announced the winners of its Transforming Cancer Therapeutics

  • What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024

    Arm's Race' Developments Five protein-design questions that still challenge AI Prix Galien USA: Domain Therapeutics Nominated for the Prestigious Best Startup Award Tectonic Therapeutic Announces Positive Phase 1a Results 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic

  • 📰 GPCR Weekly News, October 2 to 8, 2023

    This week's highlight: Congrats to our partner GPCR Therapeutics, on their expansion into fibrosis with selectivity Industry News Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets GPCR Therapeutics

  • 📰 GPCR Weekly News, August 14 to 20, 2023

    Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology GPCR Symposium on 'GPCRs as Therapeutic Modalities'. and oligomerization Molecular Insights into GPCR Mechanisms for Drugs of Abuse Industry News 'GPCR Therapeutics Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic

  • 📰 GPCR Weekly News, September 11 to 17, 2023

    Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • 📰 GPCR Weekly News, May 1 to 7, 2023

    Industry News Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 Neurocrine Biosciences Reports First Quarter 2023 Financial Results Find Therapeutics welcomes critical, we cannot think about one size fits all” Dr Pina Cardarelli, Chief Scientific Officer, GPCR Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • 📰 GPCR Weekly News, July 24 to July 30, 2023

    This week's highlights: Driving Pharma Innovation in Oncology: Domain Therapeutics' Success Proven by GPCR Symposium on GPCRs as Therapeutic Modalities is on September 22nd. Industry News Omass Therapeutics Celebrates a Series of Recent Publications by their Scientists. Discover a New Way To Develop Drugs Without Side Effects Driving Pharma Innovation in Oncology: Domain Therapeutics

  • 📰 GPCR Weekly News, June 3 to June 9, 2024

    Adhesion GPCRs A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets Services and Cube Biotech Collaborate to Enhance Cryo-EM Enabled Gene to Structure Workflow Domain Therapeutics ACTH-Dependent Cushing’s Syndrome (ADCS) Septerna Presents Preclinical Data at ENDO 2024 Highlighting Therapeutic

  • 📰 GPCR Weekly News, August 28 to September 3, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities' Showcase your project with a 1-minute abstract video Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies Confo Therapeutics 21st Annual Global Healthcare Conference CEO Raymond Stevens to Speak at STAT Future Summit on Obesity Therapeutics Function and Biased Signaling" at the DOT NEW October 3, 2023 | FREE Seminar: Changing paradigm on Therapeutics

  • Target Residence Time: The Hidden Driver of In Vivo Efficacy

    Modeling tools to understand how restricted diffusion  in tissues like tumors slows offset and improves therapeutic drug hiding in fat tissue may stay in the body for days, but if it never reaches the target site, the therapeutic

  • How Fast Does a Drug Work?

    essential for pipeline efficiency: How fast a ligand binds (k₁) and how long it stays bound (k₂)  can alter therapeutic When does onset rate dictate therapeutic onset, and when does offset rate predict duration?

  • 📰 GPCR Weekly News, July 10 to 16, 2023

    GPCRs in Cardiology, Endocrinology, and Taste Clinical, Pathophysiologic, Genetic, and Therapeutic Progress Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines OMass Therapeutics Directors Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Confo Therapeutics

  • 📰 GPCR Weekly News, October 23 to 29, 2023

    This week's highlight: Congratulations to the GPCR Therapeutics team for their publication on improving Orion's COO, Shared Innovative Insights at LSBC Central European Life Science Investment Conference GPCR Therapeutics Late-Stage Development Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics

  • 📰 GPCR Weekly News, June 26 to July 2, 2023

    GPCR Partner, Domain Therapeutics, for their nomination of the best-in-class CCR8 antibody candidate, History and function of the lactate receptor GPR81/HCAR1 in the brain: a putative therapeutic target G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics. Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening

  • 📰 GPCR Weekly News, June 24 to 30, 2024

    Bryan Roth and Brian Krumm for their study on Molecular glues as potential GPCR therapeutics Drs. breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects GPR56: A potential therapeutic via site-selective activation of mTOR GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics

  • 📰 GPCR Weekly News, August 7 to 13, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics

bottom of page